X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3309) 3309
Book Review (465) 465
Publication (356) 356
Newsletter (121) 121
Conference Proceeding (10) 10
Book Chapter (9) 9
Magazine Article (4) 4
Dissertation (3) 3
Book / eBook (1) 1
Data Set (1) 1
Paper (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3047) 3047
humans (2422) 2422
male (1586) 1586
animals (1269) 1269
oligopeptides - therapeutic use (1211) 1211
female (1189) 1189
oligopeptides - adverse effects (1031) 1031
oligopeptides - pharmacology (1006) 1006
middle aged (867) 867
oligopeptides - administration & dosage (758) 758
adult (755) 755
pharmacology & pharmacy (584) 584
mice (535) 535
aged (496) 496
treatment outcome (474) 474
rats (453) 453
drug therapy, combination (451) 451
atazanavir sulfate (433) 433
oligopeptides - chemistry (430) 430
hepatitis c, chronic - drug therapy (403) 403
antiviral agents - therapeutic use (382) 382
hiv infections - drug therapy (376) 376
peptides (367) 367
analysis (324) 324
infectious diseases (301) 301
research (298) 298
oncology (293) 293
pyridines - adverse effects (286) 286
dose-response relationship, drug (278) 278
proline - analogs & derivatives (278) 278
antiviral agents - adverse effects (274) 274
oligopeptides (270) 270
oligopeptides - pharmacokinetics (268) 268
biochemistry & molecular biology (266) 266
gastroenterology & hepatology (260) 260
drug therapy (259) 259
telaprevir (256) 256
therapy (256) 256
hepatitis c (254) 254
ribavirin - therapeutic use (254) 254
protease inhibitors (253) 253
immunology (243) 243
health aspects (240) 240
abridged index medicus (239) 239
pyridines - therapeutic use (238) 238
care and treatment (234) 234
oligopeptides - metabolism (228) 228
ribavirin (223) 223
interferon-alpha - therapeutic use (222) 222
hepacivirus - genetics (220) 220
hepatitis c virus (217) 217
cancer (216) 216
time factors (215) 215
disease models, animal (212) 212
article (203) 203
polyethylene glycols - therapeutic use (190) 190
proline - therapeutic use (188) 188
genotype (187) 187
drug interactions (185) 185
proteins (177) 177
hiv (175) 175
hiv protease inhibitors - adverse effects (172) 172
pyridines - administration & dosage (172) 172
rats, sprague-dawley (169) 169
hepacivirus - drug effects (168) 168
cell line, tumor (167) 167
expression (164) 164
viral load (162) 162
amino acid sequence (158) 158
anti-hiv agents - adverse effects (158) 158
boceprevir (155) 155
hematology (153) 153
multiple myeloma - drug therapy (153) 153
young adult (153) 153
antiviral agents (151) 151
hepatitis c - drug therapy (150) 150
in-vitro (149) 149
proteases (149) 149
recombinant proteins - therapeutic use (149) 149
drug administration schedule (146) 146
adolescent (145) 145
hiv protease inhibitors - therapeutic use (145) 145
neurosciences (144) 144
pharmacokinetics (141) 141
apoptosis (139) 139
virus-infection (138) 138
anti-hiv agents - therapeutic use (137) 137
antiviral agents - administration & dosage (137) 137
in-vivo (136) 136
clinical trials (135) 135
endocrinology & metabolism (135) 135
virology (134) 134
cells, cultured (133) 133
atazanavir (132) 132
bortezomib (132) 132
cells (131) 131
medicine (130) 130
risk factors (130) 130
medicine & public health (129) 129
hepatitis c, chronic - virology (128) 128
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3289) 3289
German (38) 38
Spanish (34) 34
Russian (28) 28
French (15) 15
Japanese (9) 9
Chinese (7) 7
Danish (4) 4
Hungarian (4) 4
Croatian (1) 1
Dutch (1) 1
Finnish (1) 1
Hebrew (1) 1
Italian (1) 1
Polish (1) 1
Swedish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of Infectious Diseases, ISSN 0022-1899, 6/2011, Volume 203, Issue 12, pp. 1791 - 1801
Background. Long-term effects of abacavir (ABC)-lamivudine (3TC), compared with tenofovir (TDF)-emtricitabine (FTC) with efavirenz (EFV) or atazanavir plus... 
HIV/AIDS | Percentage change | RNA | Spine | Bones | Bone density | Arm | Hip | Bone fractures | HIV 1 | Arts | INFECTIOUS DISEASES | EFFICACY | INITIATION | MICROBIOLOGY | PREVALENCE | IMMUNOLOGY | COMBINATION | OSTEOPOROSIS | HIV-INFECTED PATIENTS | WOMEN | THERAPY | COHORT | HEALTH | Humans | Middle Aged | Antiretroviral Therapy, Highly Active - adverse effects | Fractures, Bone - epidemiology | Male | Oligopeptides - adverse effects | Viral Load | Lamivudine - adverse effects | Tenofovir | Pyridines - adverse effects | Adenine - adverse effects | Ritonavir - adverse effects | Atazanavir Sulfate | Adult | Deoxycytidine - adverse effects | Female | Dideoxynucleosides - adverse effects | Drug Therapy, Combination | Emtricitabine | Adenine - analogs & derivatives | Osteoporosis - chemically induced | Anti-HIV Agents - adverse effects | Risk Factors | Organophosphonates - adverse effects | Benzoxazines - adverse effects | CD4 Lymphocyte Count | Absorptiometry, Photon | Bone Density - drug effects | HIV Infections - complications | Intention to Treat Analysis | HIV Infections - drug therapy | Fractures, Bone - chemically induced | Deoxycytidine - analogs & derivatives | Drug Combinations | Usage | Care and treatment | Ritonavir | Drug utilization | Lamivudine | Efavirenz | Prevention | Abacavir | Dosage and administration | Drug therapy, Combination | Drug therapy | HIV infection | Index Medicus | Abridged Index Medicus | Major and Brief Reports
Journal Article
European Journal of Gastroenterology & Hepatology, ISSN 0954-691X, 01/2015, Volume 27, Issue 1, pp. 55 - 64
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2013, Volume 59, Issue 3, pp. 434 - 441
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2011, Volume 364, Issue 25, pp. 2417 - 2428
In patients with HCV infection who did not have a sustained response to peginterferon plus ribavirin, the addition of telaprevir to this combination therapy... 
MEDICINE, GENERAL & INTERNAL | GENOTYPE 1 INFECTION | BOCEPREVIR | RIBAVIRIN | PEGINTERFERON ALPHA-2A | HEPATITIS-C | Recurrence | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins | Oligopeptides - adverse effects | Polyethylene Glycols - therapeutic use | Viral Load | Oligopeptides - therapeutic use | Serine Proteinase Inhibitors - therapeutic use | Young Adult | Serine Proteinase Inhibitors - adverse effects | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Genotype | Logistic Models | Hepatitis C, Chronic - drug therapy | Sequence Analysis, DNA | Retreatment | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Aged | Interferon-alpha - adverse effects | Peginterferon alfa-2a | Patient outcomes | Genetic aspects | Hepatitis C | Drug therapy | Comparative analysis | Health aspects | Liver diseases | Cytokines | Leukopenia | Anemia | Infections | Ribonucleic acid--RNA | Ribavirin | Manuscripts | Genotype & phenotype | Consent | Interferon | Drug dosages | Genotypes | Neutropenia | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
by Mocroft, Amanda and Kirk, Ole and Reiss, Peter and de Wit, Stephane and Sedlacek, Dalibor and Beniowski, Marek and Gatell, Jose and Phillips, Anew N and Ledergerber, Bruno and Lundgren, Jens D and Losso, M and Elias, C and Vetter, N and Zangerle, R and Karpov, I and Vassilenko, A and Mitsura, V. M and Suetnov, O and Clumeck, N and Poll, B and Colebunders, R and Vandekerckhove, L and Hadziosmanovic, V and Kostov, K and Begovac, J and Machala, L and Rozsypal, H and Sedlacek, D and Nielsen, J and Kronborg, G and Benfield, T and Larsen, M and Gerstoft, J and Katzenstein, T and Hansen, A.-B. E and Skinhøj, P and Pedersen, C and Oestergaard, L and Zilmer, K and Smidt, Jelena and Ristola, M and Katlama, C and Viard, J.-P and Girard, P.-M and Livrozet, J. M and Vanhems, P and Pradier, C and Dabis, F and Neau, D and Rockstroh, J and Schmidt, R and van Lunzen, J and Degen, O and Stellbrink, H. J and Staszewski, S and Bogner, J and Fätkenheuer, G and Kosmidis, J and Gargalianos, P and Xylomenos, G and Perdios, J and Panos, G and Filanas, A and Karabatsaki, E and Sambatakou, H and Banhegyi, D and Mulcahy, F and Yust, I and Turner, D and Burke, M and Pollack, S and Hassoun, G and Maayan, S and Chiesi, A and Esposito, R and Mazeu, I and Mussini, C and Arici, C and Pristera, R and Mazzotta, F and Gabbuti, A and Vullo, V and Lichtner, M and Chirianni, A and Montesarchio, E and Gargiulo, M and Antonucci, G and Iacomi, F and Narciso, P and Vlassi, C and Zaccarelli, M and Lazzarin, A and Finazzi, R and Galli, M and Ridolfo, A and d'Arminio Monforte, A and Rozentale, B and Aldins, P and Chaplinskas, S and Hemmer, R and ... and EuroSIDA Study Group
AIDS (London, England), ISSN 0269-9370, 2010, Volume 24, Issue 11, pp. 1667 - 1678
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2011, Volume 364, Issue 25, pp. 2405 - 2416
In patients with HCV infection and no previous treatment, the addition of telaprevir to peginterferon–ribavirin resulted in higher response rates than those... 
UNITED-STATES | TRIAL | GENETIC-VARIATION | CLEARANCE | MEDICINE, GENERAL & INTERNAL | HEPATOCELLULAR-CARCINOMA | GENOTYPE-1 PATIENTS | PEGINTERFERON ALPHA-2B | AMERICAN PATIENTS | CHRONIC HCV INFECTION | ALPHA-2B PLUS RIBAVIRIN | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins | Oligopeptides - adverse effects | Polyethylene Glycols - therapeutic use | Viral Load | Oligopeptides - therapeutic use | Serine Proteinase Inhibitors - therapeutic use | Young Adult | Serine Proteinase Inhibitors - adverse effects | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Double-Blind Method | Antiviral Agents - therapeutic use | Interferon-alpha - therapeutic use | Logistic Models | Hepatitis C, Chronic - drug therapy | Sequence Analysis, DNA | Antiviral Agents - adverse effects | Aged | Interferon-alpha - adverse effects | Peginterferon alfa-2b | Patient outcomes | Genetic aspects | Hepatitis C | Drug therapy | Comparative analysis | Health aspects | Fees & charges | Antiretroviral drugs | Liver diseases | Clinical trials | Chronic infection | Employees | Infections | Proteinase inhibitors | Genomes | Ribonucleic acid--RNA | Patients | Ribavirin | Liver cancer | Genotype & phenotype | Hepatitis | Skin | Interferon | Genotypes | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
AIDS (London, England), ISSN 0269-9370, 2012, Volume 26, Issue 5, pp. 567 - 575
Journal Article